Adverse cardiovascular effects of the coxibs.
Dogné
Jean-Michel
JM
Natural and Synthetic Drugs Research Center, University of Liège, 1, Avenue de l'Hôpital, B-36, B-4000 Liège, Belgium. Jean-Michel.Dogne@ulg.ac.be
Supuran
Claudiu T
CT
Pratico
Domenico
D
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000737:chemistry; D004335:Drug and Narcotic Control; D006801:Humans; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D018570:Risk Assessment; D013329:Structure-Activity Relationship
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases